Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.36 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BIRC2 | Q13490 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 2/20 | 0.31 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.31 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2136318 | 0.96 | CA1 (0.47) | CA2CA1ZDHHC7PDFEPHX1 | |
| SCHEMBL2137134 | 0.96 | CA1 (0.44) | CA2CA1ZDHHC7EPHX1USP2 | |
| SCHEMBL2137222 | 0.94 | CA1 (0.46) | CA2CA1ZDHHC7PDFEPHX1 | |
| SCHEMBL2140578 | 0.93 | CA1 (0.42) | CA2CA1ZDHHC7USP2LMNA | |
| SCHEMBL2138622 | 0.92 | CA1 (0.43) | CA2CA1ZDHHC7EPHX1USP2 | |
| SCHEMBL2139006 | 0.91 | ZDHHC7 (0.43) | CA2CA1ZDHHC7EPHX1USP2 | |
| SCHEMBL2133573 | 0.90 | CA1 (0.46) | CA2CA1ZDHHC7PDFEPHX1 | |
| SCHEMBL2138254 | 0.89 | CA2 (0.38) | CA2CA1EPHX1CES1MAPK1 | |
| SCHEMBL2134098 | 0.89 | CA1 (0.45) | CA2CA1ZDHHC7PDFEPHX1 | |
| SCHEMBL2134764 | 0.89 | CA1 (0.41) | CA2CA1ZDHHC7EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2664613-A1 | Process for producing amide compounds | Sumitomo Chemical Company, Limited (JP) | 2013-11-20 | — | — | EP | disclosed |
| EP-2662355-A1 | Process for producing a (fluoroalkylthio) acetonitrile | Sumitomo Chemical Company, Limited (JP) | 2013-11-13 | — | — | EP | disclosed |
| EP-2465846-A1 | PROCESS FOR PREPARATION OF (FLUOROALKYLTHIO)ACETIC ACID ESTERS | Sumitomo Chemical Company, Limited (JP) | 2012-06-20 | — | — | EP | disclosed |
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101294-A1 | PROCESS FOR PRODUCING (FLUOROALKYLTHIO) ACETIC ACID ESTER | GRHPR, AKR7A2, FAR1 | CA2 737/4885CA1 617/4885ZDHHC7 475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.